Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9462735 | 0.85 | HTR6 (0.68) | HTR6KCNH2HTR1ADRD3KHK | |
| Hydrochloric Acid SCHEMBL27751697 | 0.81 | HTR6 (0.61) | HTR6KCNH2HTR1A | |
| SCHEMBL6580736 | 0.81 | HTR6 (0.61) | HTR6KCNH2HTR1A | |
| SCHEMBL6955047 | 0.81 | DRD2 (0.52) | HTR6KCNH2HTR1ADRD3KHK | |
| SCHEMBL6583347 | 0.80 | HTR6 (0.52) | HTR6KCNH2HTR1ADRD3KHK | |
| SCHEMBL9462566 | 0.80 | HTR6 (0.56) | HTR6KCNH2HTR1ADRD3 | |
| SCHEMBL6955312 | 0.80 | HTR6 (0.48) | HTR6KCNH2HTR1ADRD3KHK | |
| SCHEMBL9150236 | 0.79 | HTR6 (0.50) | HTR6HTR1ADRD3KHK | |
| SCHEMBL10874677 | 0.78 | HTR6 (0.57) | HTR6HTR1ADRD3 | |
| SCHEMBL9150425 | 0.78 | HTR6 (0.55) | HTR6KCNH2HTR1ADRD3KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833376-B2 | 5-aminoalkyl and 5-aminocarbonyl substituted indole derivative useful for treatment of psychosis in a mammal | H. LUNDBECK A/S (DK) | 2004-12-21 | — | — | US | disclosed |
| EP-1214312-B1 | 5-AMINOALKYL AND 5-AMINOCARBONYL SUBSTITUTED INDOLES | LUNDBECK & CO AS H (DK) | 2004-04-14 | — | — | EP | disclosed |
| US-20020169169-A1 | 5-aminoalkyl and 5-aminocarbonyl substituted indoles | H. LUNDBECK A/S (DK) | 2002-11-14 | — | — | US | disclosed |
| EP-1214312-A1 | 5-AMINOALKYL AND 5-AMINOCARBONYL SUBSTITUTED INDOLES | H. LUNDBECK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001021614-A1 | 5-AMINOALKYL AND 5-AMINOCARBONYL SUBSTITUTED INDOLES | H. LUNDBECK A/S (DK) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169169-A1 | 5-aminoalkyl and 5-aminocarbonyl substituted indoles | ADRB1, ADRA2C, ADRB2 | HTR6 58/4885KCNH2 79/4885HTR1A 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.